Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Moderna stock

MRNA
US60770K1079
A2N9D9

Price

24.57
Today +/-
-0.20
Today %
-0.89 %

Moderna stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Moderna stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Moderna stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Moderna stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Moderna's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Moderna Stock Price History

DateModerna Price
5/16/202524.57 undefined
5/16/202524.79 undefined
5/15/202523.66 undefined
5/14/202524.21 undefined
5/13/202525.47 undefined
5/12/202525.65 undefined
5/9/202524.39 undefined
5/9/202524.42 undefined
5/8/202524.43 undefined
5/7/202523.51 undefined
5/6/202524.44 undefined
5/5/202527.76 undefined
5/2/202527.42 undefined
5/2/202527.67 undefined
5/1/202527.17 undefined
4/30/202528.83 undefined
4/29/202527.84 undefined
4/28/202527.36 undefined
4/25/202527.37 undefined
4/25/202527.32 undefined
4/24/202527.37 undefined
4/23/202526.66 undefined
4/22/202525.52 undefined
4/21/202525.24 undefined

Moderna Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Moderna, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Moderna from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Moderna’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Moderna. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Moderna’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Moderna’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Moderna’s growth potential.

Moderna Revenue, EBIT and net profit per share

DateModerna RevenueModerna EBITModerna Net Income
2030e11.17 B undefined0 undefined2.96 B undefined
2029e8.27 B undefined954.7 M undefined1.2 B undefined
2028e4.75 B undefined-1.54 B undefined-1.06 B undefined
2027e2.88 B undefined-2.49 B undefined-1.98 B undefined
2026e2.33 B undefined-3.29 B undefined-3.09 B undefined
2025e2.14 B undefined-4.31 B undefined-4 B undefined
20243.24 B undefined-3.45 B undefined-3.56 B undefined
20236.85 B undefined-2.04 B undefined-4.71 B undefined
202219.26 B undefined9.42 B undefined8.36 B undefined
202118.47 B undefined13.3 B undefined12.2 B undefined
2020803 M undefined-763 M undefined-747 M undefined
201960 M undefined-546 M undefined-514 M undefined
2018135 M undefined-413 M undefined-402 M undefined
2017206 M undefined-269 M undefined-270 M undefined
2016108 M undefined-224 M undefined-230 M undefined

Moderna Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.110.210.140.060.818.4719.266.853.242.142.332.884.758.2711.17
-90.74-34.47-55.561,238.332,200.254.29-64.45-52.75-33.938.9323.5365.1774.0535.04
2,099.071,100.491,679.263,778.3399.0085.8371.8863.6070.06106.0397.3478.8047.7127.4120.30
00000.815.8513.854.362.27000000
-0.23-0.27-0.4-0.51-0.7512.28.36-4.71-3.56-4-3.09-1.98-1.061.22.96
-17.3948.8927.8645.33-1,733.47-31.47-156.37-24.4612.41-22.86-35.82-46.47-212.63147.87
324324329331381431416382384000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Moderna Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Moderna is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
201620172018201920202021202220232024
                 
1.060.761.521.14.6110.739.98.67.03
0.010.010.010.011.393.181.390.890.36
44181120121279189234
00000.051.440.950.20.12
1111119233607916438365
1.090.781.561.136.316.0713.4310.338.1
0.080.140.210.290.391.382.142.662.96
0.240.150.170.160.646.848.324.742.51
0000000097
00000004440
00000005252
0.010.020.010.010.010.371.970.60.39
0.330.30.40.461.048.612.438.16.04
1.421.091.961.597.3424.6725.8618.4314.14
                 
1.181.180000000
0.030.072.542.674.84.211.170.370.87
-0.37-0.62-1.01-1.5-2.249.9618.3213.6110.05
0-1000-24-8-9.04-20.04
00-1230-362-11410
0.840.631.531.182.5614.1519.1213.8510.9
282131718302487520405
0.030.070.080.070.481.522.141.821.44
0.110.10.110.073.877.142.140.670.34
000000000
000024165161023
0.160.190.220.144.399.134.923.022.21
1316333911059991257539
000000000
400252176233277797900982996
0.410.270.210.270.391.41.811.561.04
0.580.460.430.424.7810.526.744.573.24
1.421.091.961.597.3424.6725.8618.4314.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Moderna provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Moderna's financial health and stability.

Assets

Moderna's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Moderna must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Moderna after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Moderna's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-0.22-0.26-0.38-0.51-0.7512.28.36-4.71
1521243131232348621
00000-318-559828
0.23-0.14-0.04-0.052.581.31-3.46-0.14
8181144158258338511591
00008142539
000000.482.73-0.36
0.07-0.33-0.33-0.462.0313.624.98-3.12
-33-58-105-31-67-284-400-707
-0.650.42-0.37-0.01-1.67-8.52-5.184.21
-0.620.48-0.270.02-1.6-8.24-4.784.91
00000000
0-1-20-6-140-184-270
0.4701.220.052.04-0.73-3.26-1.11
0.4701.230.052.03-0.87-3.45-1.38
011110000
00000000
-0.110.090.52-0.422.394.22-3.64-0.29
33.6-389-436.7-490.61,959.613,3364,581-3,825
00000000

Moderna stock margins

The Moderna margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Moderna. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Moderna.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Moderna's sales revenue. A higher gross margin percentage indicates that the Moderna retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Moderna's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Moderna's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Moderna's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Moderna. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Moderna's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Moderna Margin History

Moderna Gross marginModerna Profit marginModerna EBIT marginModerna Profit margin
2030e70.06 %0 %26.53 %
2029e70.06 %11.54 %14.45 %
2028e70.06 %-32.46 %-22.34 %
2027e70.06 %-86.45 %-68.91 %
2026e70.06 %-141.2 %-132.55 %
2025e70.06 %-201.57 %-187.26 %
202470.06 %-106.61 %-110.04 %
202363.6 %-29.78 %-68.84 %
202271.88 %48.9 %43.41 %
202185.83 %71.98 %66.06 %
202099 %-95.02 %-93.03 %
201970.06 %-910 %-856.67 %
201870.06 %-305.93 %-297.78 %
201770.06 %-130.58 %-131.07 %
201670.06 %-207.41 %-212.96 %

Moderna Stock Sales Revenue, EBIT, Earnings per Share

The Moderna earnings per share therefore indicates how much revenue Moderna has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Moderna earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Moderna's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Moderna’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Moderna's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Moderna Revenue, EBIT and net profit per share

DateModerna Sales per ShareModerna EBIT per shareModerna Earnings per Share
2030e29.09 undefined0 undefined7.72 undefined
2029e21.54 undefined0 undefined3.11 undefined
2028e12.38 undefined0 undefined-2.76 undefined
2027e7.49 undefined0 undefined-5.16 undefined
2026e6.07 undefined0 undefined-8.04 undefined
2025e5.57 undefined0 undefined-10.43 undefined
20248.43 undefined-8.98 undefined-9.27 undefined
202317.93 undefined-5.34 undefined-12.34 undefined
202246.31 undefined22.64 undefined20.1 undefined
202142.86 undefined30.85 undefined28.31 undefined
20202.11 undefined-2 undefined-1.96 undefined
20190.18 undefined-1.65 undefined-1.55 undefined
20180.41 undefined-1.26 undefined-1.22 undefined
20170.64 undefined-0.83 undefined-0.83 undefined
20160.33 undefined-0.69 undefined-0.71 undefined

Moderna business model

Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.com.

Moderna SWOT Analysis

Strengths

1. Innovative mRNA technology: Moderna is at the forefront of the biotechnology industry with its innovative messenger RNA (mRNA) technology, which has the potential to revolutionize vaccine and drug development.

2. Strong financial position: The company has a robust financial position, underscored by solid revenue growth and positive cash flow. This stability allows Moderna to invest in research and development and expand its operations.

3. Diverse product pipeline: Moderna has a diverse portfolio of product candidates across various therapeutic areas, including infectious diseases, cardiovascular diseases, and oncology. This diversification helps mitigate risks associated with individual product development.

Weaknesses

1. Limited commercialization experience: As a relatively young company, Moderna lacks a significant track record in successfully commercializing products. This could pose challenges in effectively bringing its pipeline candidates to market.

2. Dependency on partnerships: Moderna relies on partnerships with other pharmaceutical companies for aspects like manufacturing, distribution, and commercialization. Dependence on external collaborations may impact the company's control over these crucial processes.

3. High research and development costs: The development of mRNA-based therapeutics involves significant research and development expenses. The high costs associated with clinical trials and regulatory approvals could strain the company's financial resources.

Opportunities

1. Rising demand for mRNA-based therapeutics: The increasing demand for novel and effective treatments in various disease areas presents a significant opportunity for Moderna's mRNA technology. It has the potential to address unmet medical needs and gain substantial market share.

2. Expansion into new markets and indications: Moderna can explore new therapeutic areas and expand its product pipeline to target unexplored markets and indications. This allows the company to tap into emerging trends and diversify revenue streams.

3. Collaborative partnerships with bigger pharmaceutical companies: The company can leverage strategic partnerships with established pharmaceutical giants to enhance its manufacturing capabilities, accelerate regulatory processes, and expand global reach.

Threats

1. Intense competition: The biotechnology industry is highly competitive, with numerous players vying for market share. Moderna faces the risk of competition from larger pharmaceutical companies as well as smaller emerging biotech firms.

2. Regulatory challenges: The regulatory landscape for mRNA-based therapeutics is still evolving. Delays in obtaining regulatory approvals or changes in regulations could impact the development and commercialization timelines for Moderna's products.

3. Intellectual property risks: Protecting intellectual property related to mRNA technology and the products developed using it poses challenges, as competitors may attempt to challenge patents or develop similar technologies.

Moderna Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Moderna Revenue by Segment

Segmente2023202220192018
Net product sales6.67 B USD---
Other revenue177 M USD---
Collaboration revenue--6.2 M USD10.4 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Moderna Revenue by Segment

Segmente2023202220192018
Grant revenue94 M USD--12.56 M USD
Collaboration revenue83 M USD---
Collaboration revenue from affiliate---45.99 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Moderna Revenue by Segment

Segmente2023202220192018
Product sales-18.44 B USD--
Collaboration revenue-440 M USD--
Grant revenue-388 M USD--
Collaboration Revenue by Strategic Collaborator--82.81 M USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Moderna Revenue by Segment

Segmente2023202220192018
Collaboration revenue from related party--37.24 M USD-

Moderna Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Moderna Revenue by Segment

DateEuropeRest of worldUnited States
20231.36 B USD3.6 B USD1.9 B USD
20226.82 B USD7.3 B USD5.15 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Moderna Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Moderna historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Moderna shares outstanding

The number of shares was Moderna in 2024 — This indicates how many shares 384 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Moderna earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Moderna's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Moderna’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Moderna's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Moderna.

Moderna latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2025-3.2 -2.52  (21.22 %)2025 Q1
12/31/2024-2.74 -2.91  (-6.26 %)2024 Q4
9/30/2024-1.95 0.03  (101.54 %)2024 Q3
6/30/2024-3.45 -3.33  (3.51 %)2024 Q2
3/31/2024-3.66 -3.07  (16.04 %)2024 Q1
12/31/2023-0.99 0.55  (155.49 %)2023 Q4
9/30/2023-1.97 -9.53  (-384.77 %)2023 Q3
6/30/2023-4.12 -3.62  (12.15 %)2023 Q2
3/31/2023-1.81 0.19  (110.52 %)2023 Q1
12/31/20224.77 3.61  (-24.31 %)2022 Q4
1
2
3

Eulerpool ESG Scorecard© for the Moderna stock

Eulerpool World ESG Rating (EESG©)

78/ 100

🌱 Environment

83

👫 Social

76

🏛️ Governance

75

Environment

Scope 1 - Direct Emissions
11,240
Scope 2 - Indirect emissions from purchased energy
11,506
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
22,746
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees49
Percentage of women in management
Percentage of Asian employees27
Share of Asian management
Percentage of Hispanic/Latino employees8
Hispano/Latino Management share
Percentage of Black employees7
Black Management Share
Percentage of white employees58
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Moderna shareholders

%
Name
Stocks
Change
Date
10.46402 % The Vanguard Group, Inc.40,181,847101,25412/31/2024
10.12749 % Baillie Gifford & Co.38,889,571-3,568,51212/31/2024
4.78712 % Fidelity Management & Research Company LLC18,382,5361,283,44612/31/2024
4.69820 % BlackRock Institutional Trust Company, N.A.18,041,090471,48712/31/2024
4.57741 % State Street Global Advisors (US)17,577,236730,02412/31/2024
2.99723 % Langer (Robert S Jr.)11,509,35703/7/2024
2.35687 % Boston Biotech Ventures, L.L.C.9,050,37203/7/2024
1.90283 % Theleme Partners LLP7,306,86180,00012/31/2024
1.88577 % Geode Capital Management, L.L.C.7,241,354171,77412/31/2024
1.70960 % OCHA, L.L.C.6,564,88003/7/2024
1
2
3
4
5
...
10

Moderna Executives and Management Board

Mr. Stephane Bancel

(52)
Moderna Chief Executive Officer, Director (since 2011)
Compensation 19.88 M

Ms. Shannon Klinger

(53)
Moderna Corporate Secretary, Chief Legal Officer
Compensation 17.37 M

Mr. James Mock

(48)
Moderna Chief Financial Officer
Compensation 17.21 M

Dr. Stephen Hoge

(49)
Moderna President
Compensation 9.18 M

Dr. Noubar Afeyan

(62)
Moderna Non-Executive Independent Chairman of the Board, Co-Founder (since 2010)
Compensation 644,366
1
2
3
4

Moderna Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
AbCellera Biolog Stock
AbCellera Biolog
SupplierCustomer0,850,800,790,950,74
Catalent Stock
Catalent
SupplierCustomer0,840,500,730,920,860,86
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,600,670,780,900,140,65
Omnicom Stock
Omnicom
SupplierCustomer0,530,600,79-0,53-0,580,44
Roche Holding Stock
Roche Holding
SupplierCustomer0,350,45-0,230,16-0,100,50
Fusion Antibodies Stock
Fusion Antibodies
SupplierCustomer0,320,34-0,120,800,790,14
Vertex Pharmaceuticals Incorporated Stock
Vertex Pharmaceuticals Incorporated
SupplierCustomer0,210,630,26-0,65-0,76-0,71
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,190,55-0,05-0,58-0,570,08
AstraZeneca PLC Stock
AstraZeneca PLC
SupplierCustomer0,180,450,47-0,52-0,420,30
Laboratorios Farmaceutico Stock
Laboratorios Farmaceutico
SupplierCustomer0,150,280,560,36-0,480,60
1

Most common questions regarding Moderna

What values and corporate philosophy does Moderna represent?

Moderna Inc represents a commitment to pioneering transformative medicines based on messenger RNA (mRNA) technology. The company's corporate philosophy centers around innovation, collaboration, and patient-focused progress. Moderna believes in leveraging its proprietary mRNA platform to develop a vast range of potential therapeutics and vaccines to tackle various diseases. The company strives to address unmet medical needs and improve global healthcare through its cutting-edge research and development efforts. Moderna's dedication to scientific excellence, forward-thinking strategies, and ongoing partnerships positions it as a leader in the biotechnology industry, driving breakthroughs and shaping the future of medicine.

In which countries and regions is Moderna primarily present?

Moderna Inc is primarily present in several countries and regions worldwide. The company has its headquarters in Cambridge, Massachusetts, United States. Apart from the US, Moderna Inc has a notable presence in various countries and regions such as Europe, including the United Kingdom, Germany, France, and Switzerland. Additionally, Moderna Inc operates in Asia, with a presence in Japan and South Korea. The company also has collaborations and partnerships with organizations and institutions globally, enabling its presence in diverse regions for the development and distribution of its innovative mRNA-based vaccines and therapies.

What significant milestones has the company Moderna achieved?

Moderna Inc, a renowned biotechnology company, has achieved several significant milestones. Notably, Moderna became the first company to release an mRNA-based vaccine authorized for emergency use against COVID-19, known as the Moderna COVID-19 Vaccine. This breakthrough marked a monumental achievement in the fight against the global pandemic. Additionally, Moderna has made remarkable progress in advancing mRNA-based therapies for various diseases, including cancer and rare genetic disorders. Through strategic collaborations and cutting-edge research, Moderna has demonstrated its commitment to revolutionize medicine by harnessing the power of mRNA technology. Moderna Inc's dedication to innovation and groundbreaking achievements position it as a leading player in the biotech industry.

What is the history and background of the company Moderna?

Moderna Inc, a leading biotechnology company, was founded in 2010. Headquartered in Cambridge, Massachusetts, Moderna specializes in the development of mRNA-based medicines and therapies. By utilizing the potential of messenger RNA (mRNA) technology, the company aims to revolutionize the field of medicine. Moderna has a diverse pipeline of investigational programs, targeting various diseases, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. The company's commitment to innovation and cutting-edge research has attracted strategic collaborations with renowned organizations and industry leaders. With its groundbreaking approach and promising advancements, Moderna Inc continues to make significant contributions to the biomedical field.

Who are the main competitors of Moderna in the market?

Moderna Inc faces competition from various companies in the market, including established pharmaceutical giants such as Pfizer, Johnson & Johnson, and AstraZeneca. These competitors also focus on developing and distributing vaccines and therapeutics, much like Moderna Inc. However, Moderna Inc stands out for its pioneering messenger RNA (mRNA) technology, which has gained significant attention and recognition. With its innovative approach and potential for addressing unmet medical needs, Moderna Inc continues to position itself as a prominent player in the biopharmaceutical industry and compete against other industry leaders in the market.

In which industries is Moderna primarily active?

Moderna Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Moderna?

Moderna Inc is a biotechnology company with a business model that focuses on the development and commercialization of mRNA-based therapeutics and vaccines. The company utilizes mRNA technology to create personalized medicine and improve healthcare outcomes. With an emphasis on infectious diseases, rare diseases, and oncology, Moderna Inc leverages its platform to develop a diverse pipeline of innovative treatments. By harnessing the potential of mRNA, Moderna Inc aims to revolutionize the way diseases are prevented and treated, offering new hope and possibilities for patients globally.

What is the P/E ratio of Moderna 2025?

The Moderna P/E ratio is -2.36.

What is the P/S ratio of Moderna 2025?

The Moderna P/S ratio is 4.41.

What is the Quality Investing of Moderna?

The Quality Investing for Moderna is 1/10.

What is the revenue of Moderna 2025?

The expected Moderna revenue is 2.14 B USD.

How high is the profit of Moderna 2025?

The expected Moderna profit is -4 B USD.

What is the business model of Moderna

Moderna Inc is a biotechnology company focused on the development and production of mRNA therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts, USA. The core divisions of Moderna Inc include research and development, production, and marketing of mRNA-based therapeutics and vaccines. In the field of research and development, Moderna Inc is working to discover and develop new therapies and vaccines for a variety of diseases. The company has a broad range of therapy areas such as immuno-oncology, infectious diseases, rare diseases, autoimmune diseases, and cardiovascular diseases. Moderna Inc's product line includes mRNA-based therapeutics and vaccines. The company has already conducted several clinical trials in various therapy areas, including cancer, heart attack, and influenza. The company has also developed and produced vaccines against COVID-19, which have already been approved by many countries and used by millions of people worldwide. Moderna Inc also operates a production facility in Massachusetts, USA. The company has a proven ability to rapidly and on a large scale produce mRNA-based products, enabling it to quickly respond to epidemics and pandemics, as was the case with the COVID-19 pandemic. Moderna Inc's business model is based on the commercialization of mRNA-based therapeutics and vaccines. The company leverages its advanced technology and state-of-the-art production processes to develop fast and effective solutions for fighting diseases. The company has also formed partnerships with other companies, government agencies, and universities around the world to share and expand its technology and expertise. Moderna Inc is a publicly traded company listed on the Nasdaq stock exchange in the USA. The company has a strong financial structure and has a wide range of investors and partners worldwide. Overall, Moderna Inc has an innovative and promising business model. By developing and producing mRNA-based products, the company is contributing to fighting a wide range of diseases and improving the well-being of people worldwide. With its strong market position and advanced technology, the company is well-positioned to continue growing and succeeding in the future.

What is the Moderna dividend?

Moderna pays a dividend of 0 USD distributed over payouts per year.

How often does Moderna pay dividends?

The dividend cannot currently be calculated for Moderna or the company does not pay out a dividend.

What is the Moderna ISIN?

The ISIN of Moderna is US60770K1079.

What is the Moderna WKN?

The WKN of Moderna is A2N9D9.

What is the Moderna ticker?

The ticker of Moderna is MRNA.

How much dividend does Moderna pay?

Over the past 12 months, Moderna paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moderna is expected to pay a dividend of 0 USD.

What is the dividend yield of Moderna?

The current dividend yield of Moderna is .

When does Moderna pay dividends?

Moderna pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moderna?

Moderna paid dividends every year for the past 0 years.

What is the dividend of Moderna?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moderna located?

Moderna is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moderna kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moderna from 5/19/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/19/2025.

When did Moderna pay the last dividend?

The last dividend was paid out on 5/19/2025.

What was the dividend of Moderna in the year 2024?

In the year 2024, Moderna distributed 0 USD as dividends.

In which currency does Moderna pay out the dividend?

The dividends of Moderna are distributed in USD.

All fundamentals about Moderna

Our stock analysis for Moderna Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Moderna Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.